Filters

Clear all

Expert Opinion

Plain Language Summary

Expert Review

Text Availability

Abstract

Full text

Free full text

Publication Types

Journal Article

Research Support, Non-U.S. Gov't

Randomized Controlled Trial

Clinical Trial

Comparative Study

Review

Multicenter Study

Clinical Trial, Phase III

Systematic Review

Research Support, U.S. Gov't, Non-P.H.S.

Research Support, N.I.H., Extramural

Evaluation Study

Congress

Controlled Clinical Trial

Publication Year

From

Quick links

Individual year

2022

2021

2018

2017

2014

2013

2010

2008

2007

2006

2005

2004

2003

2002

2001

Sort by:

selected

Print page

Email selected articles

Favourite selected articles

Create a NED Search Alert for this search

Save this search

Advanced Search

Run an advanced search

Results for
""Goserelin""[mesh_terms]

22 Results

Searching titles within these results

Luteinising hormone releasing hormone analogues in the treatment of prostate cancer.

Lyndon M Gommersall, Dickon Hayne, Iqbal S Shergill, Manit Arya, D M A Wallace

Expert opinion on pharmacotherapy 2003;3(12):1685-92

Full Text

Abstract

Highlights from the 39th Annual meeting of the American Society of Clinical Oncology Chicago, Illinois.

Preeta Tyagi, Jennifer Klem, Amy D'Orazio

Clinical prostate cancer 2004;2(2):73-9

Full Text

Estrogen therapy in patients with prostate cancer: a contemporary systematic review.

Herney Andrés García-Perdomo, Emerson Luis Zani, Leonardo Oliveira Reis

International urology and nephrology 2018;50(6):993-1003

Full Text

Abstract

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.

Hiroyuki Takahashi, Shin Egawa, Manabu Aoki, Masahito Kido, Hiroshi Sasaki, Kenta Miki

BMC cancer 2017;16(1):708

Free Full Text

Abstract

Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

Frances Dockery, Christopher J Bulpitt, Sanjiv Agarwal, Mandy Donaldson, Chakravarthi Rajkumar

Clinical science (London, England : 1979) 2003;104(2):195-201

Full Text

Abstract

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer.

Ho Hyun Ryu, Sei Hyun Ahn, Hee Jung Shin, Hee Jeong Kim, Gyung Yub Gong, Hak Hee Kim, Byung Ho Son, Jong Won Lee, Beom Seok Ko, Sung-Bae Kim, Kyung Hae Jung, Jin-Hee Ahn, Ji Sun Kim, Jeong Eun Kim, Seon Ok Kim

Scientific reports 2021;11(1):10510

Free Full Text

Abstract

Hormonal therapy of prostate cancer.

Frans Debruyne

Seminars in urologic oncology 2002;20(3 Suppl 1):4-9

Full Text

Abstract

Effects of acute ovarian hormone suppression on the human brain: an in vivo 1H MRS study.

Michael C Craig, Eileen M Daly, Ruth O'Gorman, Janice Rymer, David Lythgoe, Ginny Ng, Andrew Simmons, Pauline M Maki, Declan G M Murphy

Psychoneuroendocrinology 2008;32(8-10):1128-32

Full Text

Abstract

Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study.

Klavs Madsen, Thue Kvorning, Kim Brixen, Marianne Andersen

American journal of physiology. Endocrinology and metabolism 2006;291(6):E1325-32

Free Full Text

Abstract

Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.

Thine Hvid, Kamilla Winding, Anders Rinnov, Thomas Dejgaard, Carsten Thomsen, Peter Iversen, Klaus Brasso, Kari J Mikines, Gerrit van Hall, Birgitte Lindegaard, Thomas P J Solomon, Bente K Pedersen

Endocrine-related cancer 2014;20(5):621-32

Full Text

Abstract

Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.

Chuanfa Guo, Eliot Siegel, Brenda Dorsey, Christine Engstrom, Pradip Amin, Nancy Dawson, Arif Hussain

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2789-96

Full Text

Abstract

Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study.

Peter Kann, Mathias Muth, Monika Baier, Katrin Birkholz, May Ziller, Annette Kauka, Peyman Hadji

Breast cancer research and treatment 2014;144(2):343-51

Full Text

Abstract

Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.

Etsuko Isahaya, Noboru Hara, Tsutomu Nishiyama, Tatsuhiko Hoshii, Itsuhiro Takizawa, Kota Takahashi

The Prostate 2010;70(2):155-61

Full Text

Abstract

Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.

Adetunji T Toriola, Laura E Simon, Malika Rakhmankulova, Ana S Salazar

JNCI cancer spectrum 2022;5(1):pkaa125

Free Full Text

Abstract

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.

A Hussain, N Dawson, P Amin, M Naslund, C Engstrom, T Chen

Seminars in oncology 2001;28(4 Suppl 15):22-31

Full Text

Abstract

Results: 1 – 15 / 22

Filters

Expert Opinion

Text Availability

Publication Types

Publication Year

Results for ""Goserelin""[mesh_terms]

Luteinising hormone releasing hormone analogues in the treatment of prostate cancer.

Highlights from the 39th Annual meeting of the American Society of Clinical Oncology Chicago, Illinois.

Estrogen therapy in patients with prostate cancer: a contemporary systematic review.

A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.

Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia.

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer.

Hormonal therapy of prostate cancer.

Effects of acute ovarian hormone suppression on the human brain: an in vivo 1H MRS study.

Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study.

Endurance training improves insulin sensitivity and body composition in prostate cancer patients treated with androgen deprivation therapy.

Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.

Effect of adjuvant endocrine therapy on hormonal levels in premenopausal women with breast cancer: the ProBONE II study.

Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis.

Chemoprevention Agents to Reduce Mammographic Breast Density in Premenopausal Women: A Systematic Review of Clinical Trials.

Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.

Results for
""Goserelin""[mesh_terms]